ArticleVaccines2022

Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate.

Ileanet Ávalos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.